Neurological and Mental Health ConditionsMAMSNCT07432217
Mapping Antenatal Maternal Stress
An observational study of Neurological and Mental Health Conditions and Genetic Susceptibility, run by Institute for Human Development and Potential (IHDP), Singapore at 1 site in Singapore.
Trial summary
This study recruits women from early-mid pregnancy and later follows their children after birth, tracking both the mother and child until the child reaches at least 4 years of age. Read more about this study
- Who is it for?
- Ages 21 to 40 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Neurological and Mental Health Conditions, Genetic Susceptibility, Socioeconomic Factors
- How many people
- 1,419 participants
- Where
- 1 siteSingapore
- Study dates
- 30 Sep 2019to 16 Jun 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 40 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: Singapore
Who may be able to join
- Mothers aged 21 - 40 years
- Below 24 weeks of pregnancy by ultrasonography
- Proficient and able to respond to questionnaires in English
- Intends for herself and her child to stay in Singapore for the next 5 years
- Access to a smartphone or standard laptop/desktop
- All participants whose data on pregnancy follow-up and delivery would be available from healthcare professionals
- Willing to take part in this study and able to provide written consent
Who cannot join
- Women with pre-existing or a history of psychotic depression, schizophrenia and bipolar disorders
- Women currently on oral/IV steroids and/or thyroids medication
- Women with a history of thyroid disease
- Women who are pregnant via any assisted reproduction
- Women carrying multiples
- Women currently enrolled into any interventional randomized controlled trials
Trial locations and contacts
1 site in 1 country.
Singapore1 site
Institute for Human Development and Potential
Singapore, 117609
About this study
Official title: Mapping Antenatal Maternal Stress (MAMS)
This study recruits women from early-mid pregnancy and later follows their children after birth, tracking both the mother and child until the child reaches at least 4 years of age. The study aims to examine the determinants of maternal mental health during pregnancy and how genetic factors could influence maternal mental health and child outcomes.
Read the detailed description
Prenatal maternal mental health has a significant long-lasting impact on both maternal functioning and child development. In Singapore and other developed nations, approximately 40% of pregnant women report symptoms of depression or anxiety at levels that predict poor maternal psychosocial functioning, as well as altered neurodevelopment and emotional-cognitive difficulties in their children. Despite the high prevalence and well-established consequences of prenatal mood disorders, the biological mechanisms underlying these conditions remain poorly understood. Prior research has implicated stress hormones, gonadal steroids, and genes, particularly within the serotonergic system, in contributing to perinatal depression and anxiety. However, candidate gene approaches have limitations. Mental health disorders arise from the combined effects of multiple genetic variants across distributed networks, rather than isolated loci. This understanding has led to the use of polygenic risk scores (PRS), which aggregate genetic variants associated with psychiatric conditions, to capture cumulative biological susceptibility. This MAMS study aims to build a predictive model for maternal antenatal i) anxiety, ii) depression, as well as iii) identify the genomic contribution to a composite score representing maternal mental health/well-being across a series of instruments. The research will also examine predictors of co-morbid conditions, notably depression and anxiety, where the effects on child developmental outcomes appear to be greater. Participants will be followed up from pregnancy through the child turning at least four years old. A subset of participants is enrolled in a sub-study Mapping Antenatal Maternal Stress - Child Outcomes (MAMS-CO).
Data will be collected through questionnaires done online, biological samples collection, and assessments done during lab-based visits.
- Questionnaires related to depression, anxiety, psychosocial risk factors such as life stressors, social and partner support, socioeconomic factors, medical history, behavior, cognition, lifestyle, health status, parental bonding, childhood adversity experienced, socio-emotional factors, executive function, family dynamics, sleep quality, personality traits
- Collection of samples such as blood, buccal swabs, and saliva
- Sleep actigraphy measures on pregnant mothers and infants
- Child developmental assessments
- Conditions
- Neurological and Mental Health Conditions, Genetic Susceptibility, Socioeconomic Factors, Psychology, Social
- Keywords
- Neurodevelopment, Genetics, Mental Health
- Medical subject headings
- Neurologic Manifestations, Genetic Predisposition to Disease, Psychological Well-Being
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Pregnant mothers, infants and children | Mothers who are aged 21 - 40 years, below 24 weeks of pregnancy by ultrasonography, are willing to respond to questionnaires in English, and intend to stay in Singapore with her child for the next 5 years are eligible for the study. Babies born from these mothers will be followed up until the child is at least 4 years old. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cumulative psychosocial risk index of maternal depression and anxiety
To create a cumulative risk index by collecting data using existing validated measures on known risk factors for maternal depression and anxiety, including 1) low socio-economic status, 2) poor marital relations, 3) low social support, 4) high levels of perceived stress, 5) high levels of neuroticism, 6) low self-esteem, 7) poor family function, and 8) childhood adversity in the form of maltreatment and/or poor parental relations.
Measured: From pregnancy up to 2 years postnatal
Polygenic risk score for differential susceptibility to environmental susceptibility
To identify genotypic variation associated with perinatal maternal mental health
Measured: From pregnancy up to 2 years postnatal
Determinants of maternal symptoms of depression and anxiety with those that predict positive maternal mental health
To compare the determinants of maternal symptoms of depression and anxiety with those that predict the level of positive mental health
Measured: From pregnancy up to 2 years postnatal
Secondary outcomes (3)
Influence of perinatal maternal mental health in relation to child development outcomes
To examine the impact of perinatal maternal mental health on child development outcomes using standardized clinical measures that have predictive validity for cognitive, emotional and social outcomes in young children. Our analyses will feature candidate moderators of the association between maternal mental health and child outcomes, including socioeconomic status, family cohesion and parental attitudes. We will also examine the moderating influence of the polygenic risk scores in determining the strength of the association between maternal mental health and specific child cognitive - emotional outcomes.
Measured: From pregnancy to postnatal 6 years
Determine specific contribution of maternal prenatal mood factor components to specific developmental outcomes in children
Analyses of maternal prenatal mood factors (e.g., maternal positive mental health, somatic complaints, anxiety, etc.) to determine which components contribute to specific developmental outcomes in children.
Measured: From pregnancy to postnatal 6 years
Influence of genetic susceptibility on maternal mental health and child outcomes
Exploratory analysis of the hypothesized moderating effect of the polygenic risk scores to examine those SNP's that best account for the association between the psychosocial risk index, maternal mental health and child outcomes.
Measured: From pregnancy to postnatal 6 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2026
- Study start30 Sep 2019
- Primary completionJun 2029 (estimated)
- Study completion16 Jun 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neurological and Mental Health ConditionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,419 participants (actual)
Sponsor and investigators
- Lead sponsor
- Institute for Human Development and Potential (IHDP), Singapore
- Sponsor type
- University, hospital or other
- Collaborators
- National University Hospital, Singapore, Institute of Mental Health, Singapore, KK Women's and Children's Hospital, McGill University
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07432217
- Sponsor's protocol ID
- 2018/00967
- Other IDs
- 2018
- Acronym
- MAMS
- Status last verified
- Feb 2026
- First submitted
- 12 Feb 2026
- Last updated
- 25 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mapping Antenatal Maternal Stress (MAMS)
- ClinicalTrials.gov ID
- NCT07432217
- Acronym / sponsor ID
- MAMS / 2018/00967
- Conditions
- Neurological and Mental Health Conditions, Genetic Susceptibility, Socioeconomic Factors, Psychology, Social
- Keywords
- Neurodevelopment, Genetics, Mental Health
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,419 participants (actual)
- Lead sponsor
- Institute for Human Development and Potential (IHDP), SingaporeUniversity, hospital or other
- Collaborators
- National University Hospital, Singapore, Institute of Mental Health, Singapore, KK Women's and Children's Hospital, McGill University
- Study start
- 30 Sep 2019 (actual)
- Primary completion
- Jun 2029 (estimated)
- Study completion
- 16 Jun 2029 (estimated)
- First posted
- 25 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study recruits women from early-mid pregnancy and later follows their children after birth, tracking both the mother and child until the child reaches at least 4 years of age. The study aims to examine the determinants of maternal mental health during pregnancy and how genetic factors could influence maternal mental health and child outcomes.
Detailed description
Prenatal maternal mental health has a significant long-lasting impact on both maternal functioning and child development. In Singapore and other developed nations, approximately 40% of pregnant women report symptoms of depression or anxiety at levels that predict poor maternal psychosocial functioning, as well as altered neurodevelopment and emotional-cognitive difficulties in their children. Despite the high prevalence and well-established consequences of prenatal mood disorders, the biological mechanisms underlying these conditions remain poorly understood. Prior research has implicated stress hormones, gonadal steroids, and genes, particularly within the serotonergic system, in contributing to perinatal depression and anxiety. However, candidate gene approaches have limitations. Mental health disorders arise from the combined effects of multiple genetic variants across distributed networks, rather than isolated loci. This understanding has led to the use of polygenic risk scores (PRS), which aggregate genetic variants associated with psychiatric conditions, to capture cumulative biological susceptibility. This MAMS study aims to build a predictive model for maternal antenatal i) anxiety, ii) depression, as well as iii) identify the genomic contribution to a composite score representing maternal mental health/well-being across a series of instruments. The research will also examine predictors of co-morbid conditions, notably depression and anxiety, where the effects on child developmental outcomes appear to be greater. Participants will be followed up from pregnancy through the child turning at least four years old. A subset of participants is enrolled in a sub-study Mapping Antenatal Maternal Stress - Child Outcomes (MAMS-CO).
Data will be collected through questionnaires done online, biological samples collection, and assessments done during lab-based visits.
- Questionnaires related to depression, anxiety, psychosocial risk factors such as life stressors, social and partner support, socioeconomic factors, medical history, behavior, cognition, lifestyle, health status, parental bonding, childhood adversity experienced, socio-emotional factors, executive function, family dynamics, sleep quality, personality traits
- Collection of samples such as blood, buccal swabs, and saliva
- Sleep actigraphy measures on pregnant mothers and infants
- Child developmental assessments
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pregnant mothers, infants and children | – | –Mothers who are aged 21 - 40 years, below 24 weeks of pregnancy by ultrasonography, are willing to respond to questionnaires in English, and intend to stay in Singapore with her child for the next 5 years are eligible for the study. Babies born from these mothers will be followed up until the child is at least 4 years old. |
Who may qualify
- Ages
- 21 to 40 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Singapore
Key inclusion criteria (7 listed)
- Mothers aged 21 - 40 years
- Below 24 weeks of pregnancy by ultrasonography
- Proficient and able to respond to questionnaires in English
- Intends for herself and her child to stay in Singapore for the next 5 years
- Access to a smartphone or standard laptop/desktop
Key exclusion criteria (6 listed)
- Women with pre-existing or a history of psychotic depression, schizophrenia and bipolar disorders
- Women currently on oral/IV steroids and/or thyroids medication
- Women with a history of thyroid disease
- Women who are pregnant via any assisted reproduction
- Women carrying multiples
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cumulative psychosocial risk index of maternal depression and anxiety
Time frame: From pregnancy up to 2 years postnatal
To create a cumulative risk index by collecting data using existing validated measures on known risk factors for maternal depression and anxiety, including 1) low socio-economic status, 2) poor marital relations, 3) low social support, 4) high levels of perceived stress, 5) high levels of neuroticism, 6) low self-esteem, 7) poor family function, and 8) childhood adversity in the form of maltreatment and/or poor parental relations.
Polygenic risk score for differential susceptibility to environmental susceptibility
Time frame: From pregnancy up to 2 years postnatal
To identify genotypic variation associated with perinatal maternal mental health
Determinants of maternal symptoms of depression and anxiety with those that predict positive maternal mental health
Time frame: From pregnancy up to 2 years postnatal
To compare the determinants of maternal symptoms of depression and anxiety with those that predict the level of positive mental health
3 secondary outcomes
Influence of perinatal maternal mental health in relation to child development outcomes
Time frame: From pregnancy to postnatal 6 years
Determine specific contribution of maternal prenatal mood factor components to specific developmental outcomes in children
Time frame: From pregnancy to postnatal 6 years
Influence of genetic susceptibility on maternal mental health and child outcomes
Time frame: From pregnancy to postnatal 6 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Feb 2026.
Related trials for Neurological and Mental Health Conditions
Not yet recruiting
AI-Powered Sleep Hygiene Mentor for Adults Living With HIV
Sleep Wake Disorders, Sleep Initiation and Maintenance Disorders
Not yet recruitingObservational study
Prospective Observational Multimodal Neuromonitoring During High-Risk Adult Surgery
Postoperative Cognitive Complications, Delirium
Active, not recruiting
Future Planning and Well-Being for Individuals With Intellectual Disabilities and Family Caregivers
Intellectual Disability
Active, not recruiting
Pai.ACT: AI-Driven ACT Chatbot for Mental Health Triage and Service Evaluation
Autism Spectrum Disorder, Attention Deficit Disorder With Hyperactivity (ADHD)
Not yet recruiting
Two Sessions of Coach-Delivered Core Transformation for Distress and Well-Being
Psychological Distress, Psychological Well-being
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neurological and Mental Health Conditions and Genetic Susceptibility, run by Institute for Human Development and Potential (IHDP), Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 25 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cumulative psychosocial risk index of maternal depression and anxiety (time frame: From pregnancy up to 2 years postnatal). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2026.